Conjugation of a Cryptococcus neoformans-derived metalloprotease to antifungal-loaded PLGA nanoparticles treats neural cryptococcosis in an in vitro model
PLOS One · 2026
DOI: 10.1371/journal.pone.0340202 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Dylan M Lanser und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Medicine, University of California, Davis, California, United States of America. Hauptthemen laut MEDLINE: Cryptococcus neoformans, Antifungal Agents, Nanoparticles, Lactic Acid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIAID NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Overcoming the blood-brain barrier to deliver therapeutics is a major hurdle in treating diseases of the central nervous system. We engineered 4-arm carboxyl terminated poly(D,L-lactide-co-glycolide) nanoparticles with the fungal metalloprotease Mpr1, an enzyme utilized by the neurotropic pathogen Cryptococcus neoformans ( Cn ) to cross the blood-brain barrier. Nanoparticles were prepared using a modified single emulsion solvent evaporation technique, and characterized in terms of shape, size, zeta potential, encapsulation efficiency, and toxicity to brain microvascular endothelial cells. Mpr1-functionalized nanoparticles had increased penetration over non-functionalized nanoparticles in an in vitro model of the blood-brain barrier. When encapsulating amphotericin B, a potent antifungal drug, Mpr1-functionalized nanoparticles reduced fungal burden in an in vitro model of neural cryptococcosis. Loaded nanoparticles also had an 8-fold lower minimum inhibitory concentration against Cn and Candida albicans ( Ca ) compared to unencapsulated amphotericin B. Results indicate that Mpr1-coating of polymeric nanoparticles is a promising strategy to enhance drug delivery to the brain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Medicine, University of California, Davis, California, United States of America.
- Department of Biomedical Engineering, University of California, Davis, California, United States of America.
- J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, Florida, United States of America.
ORCID-Profile: Adam Turner, Angie Gelli
Förderung
- NINDS NIH HHS
- NIAID NIH HHS
- NIGMS NIH HHS
- National Institutes of Health
Zitieren
APA
Lanser, D. M., Turner, A., Pacifici, N., Vu, K., Lewis, J., & Gelli, A. (2026). Conjugation of a Cryptococcus neoformans-derived metalloprotease to antifungal-loaded PLGA nanoparticles treats neural cryptococcosis in an in vitro model. PLOS One. https://doi.org/10.1371/journal.pone.0340202
Vancouver
Lanser DM, Turner A, Pacifici N, Vu K, Lewis J, Gelli A. Conjugation of a Cryptococcus neoformans-derived metalloprotease to antifungal-loaded PLGA nanoparticles treats neural cryptococcosis in an in vitro model. PLOS One. 2026. doi:10.1371/journal.pone.0340202
BibTeX
@article{Lanser2026,
author = {Lanser, Dylan M and Turner, Adam and Pacifici, Noah and Vu, Kiem and Lewis, Jamal and Gelli, Angie},
title = {Conjugation of a Cryptococcus neoformans-derived metalloprotease to antifungal-loaded PLGA nanoparticles treats neural cryptococcosis in an in vitro model},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0340202}
}
EUVIMED